A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target

Despite the development of newer anti-seizure medications over the past 50 years, 30–40% of patients with epilepsy remain refractory to treatment. One explanation for this lack of progress is that the current screening process is largely biased towards transmembrane channels and receptors, and ignor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibhazehiebo, Kingsley, Gavrilovici, Cezar, de la Hoz, Cristiane L, Ma, Shun-Chieh, Rehak, Renata, Kaushik, Gaurav, Meza Santoscoy, Paola L, Scott, Lucas, Nath, Nandan, Kim, Do-Young, Rho, Jong M, Kurrasch, Deborah M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837409/
https://www.ncbi.nlm.nih.gov/pubmed/29373639
http://dx.doi.org/10.1093/brain/awx364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837409/
https://www.ncbi.nlm.nih.gov/pubmed/29373639
http://dx.doi.org/10.1093/brain/awx364

Ejemplares similares